相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon
Lucio Boglione et al.
ANTIVIRAL RESEARCH (2014)
Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC)
Rodolfo Passalacqua et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Charles G. Drake et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women
Fabiana Cannella et al.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2014)
Epigenetic Reprogramming of the Type III Interferon Response Potentiates Antiviral Activity and Suppresses Tumor Growth
Siyuan Ding et al.
PLOS BIOLOGY (2014)
Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C
Maria A. Jimenez-Sousa et al.
BMC MEDICINE (2013)
Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress
Lei Zhang et al.
CANCER LETTERS (2013)
Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10
Christoph Burkart et al.
EMBO MOLECULAR MEDICINE (2013)
Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms
Brady L. Stein et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2013)
Interferon-Alpha in the Treatment of Multiple Myeloma
Khoo
CURRENT DRUG TARGETS (2012)
Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells
Yasuhiro Tezuka et al.
LUNG CANCER (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects
Q. Li et al.
BRITISH JOURNAL OF CANCER (2011)
Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer
Hitomi Fujie et al.
CANCER SCIENCE (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects
Masatoshi Tagawa et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Interferon Lambda: A New Sword in Cancer Immunotherapy
Ahmed Lasfar et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Antitumor activity of Type I and Type III interferons in BNL hepatoma model
Walid Abushahba et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer
Phonphimon Wongthida et al.
CANCER RESEARCH (2010)
The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
S. Pasquali et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents
Quanhai La et al.
EUROPEAN JOURNAL OF CANCER (2010)
Interferon-Lambda as a Potential Therapeutic Agent in Cancer Treatment
Hakan C. Steen et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2010)
Interleukin-29 Binds to Melanoma Cells Inducing Jak-STAT Signal Transduction and Apoptosis
Kristan D. Guenterberg et al.
MOLECULAR CANCER THERAPEUTICS (2010)
IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells
Jihong Dai et al.
BLOOD (2009)
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines
K. Witte et al.
GENES AND IMMUNITY (2009)
Interferon-λ Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family
Hans Henrik Gad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity
Stephen G. Maher et al.
CANCER BIOLOGY & THERAPY (2008)
Regulation of apoptosis by type III interferons
W. Li et al.
CELL PROLIFERATION (2008)
An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity
Nina Ank et al.
JOURNAL OF IMMUNOLOGY (2008)
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes
Kerstin Wolk et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo
Caroline Sommereyns et al.
PLOS PATHOGENS (2008)
IL-28 elicits antitumor responses against murine fibrosarcoma
Muneo Numasaki et al.
JOURNAL OF IMMUNOLOGY (2007)
Human interferon lambda-1 (IFN-λ1/IL-29) modulates the Th1/Th2 response
W. J. Jordan et al.
GENES AND IMMUNITY (2007)
Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells
Kathrin Zitzmann et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Antitumor activity of IFN-ℷ in murine tumor models
Atsuko Sato et al.
JOURNAL OF IMMUNOLOGY (2006)
Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo
N Ank et al.
JOURNAL OF VIROLOGY (2006)
Characterization of the mouse IFN-λ ligand-receptor system:: IFN-λs exhibit antitumor activity against B16 melanoma
A Lasfar et al.
CANCER RESEARCH (2006)
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial:: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
UR Kleeberg et al.
EUROPEAN JOURNAL OF CANCER (2004)
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1 -: Similarities with type I interferon signaling
L Dumoutier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3
L Dumoutier et al.
BIOCHEMICAL JOURNAL (2003)
IL-28, IL-29 and their class II cytokine receptor IL-28R
P Sheppard et al.
NATURE IMMUNOLOGY (2003)
IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex
SV Kotenko et al.
NATURE IMMUNOLOGY (2003)
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
N Cascinelli et al.
LANCET (2001)
分享论文
